Ajay Devgn moves Bombay HC over FDA’s pan masala ad notice
Source Entity
TNN
Bollywood actors Ajay Devgn, Shah Rukh Khan, and Tiger Shroff are facing legal scrutiny from the Maharashtra FDA over surrogate advertising of Vimal Pan Masala. Ajay Devgn has challenged the show-cause notice in the Bombay High Court, labeling the action arbitrary as the legal focus shifts to the adjudication stage.
The Legal Battle Over Surrogate Advertising
Bollywood superstar Ajay Devgn has officially initiated legal proceedings in the Bombay High Court, challenging a show-cause notice issued by the Maharashtra Food and Drug Administration (FDA). The dispute centers on television and digital advertisements for 'Vimal Elaichi,' which the FDA alleges serve as a surrogate promotional vehicle for 'Vimal Pan Masala,' a chewable product classified as a prohibited smokeless tobacco item within the state. This high-profile case highlights the ongoing friction between the entertainment industry’s lucrative endorsement deals and the regulatory mandates governing public health.
The Scope of Regulatory Scrutiny
Beyond Ajay Devgn, the Maharashtra FDA has cast a wide net, issuing similar show-cause notices to other prominent actors, including Shah Rukh Khan and Tiger Shroff. The regulatory body’s position is that these celebrities are effectively promoting a banned substance under the guise of an 'elaichi' (cardamom) brand. FDA Commissioner Tukaram Mundhe confirmed that while all three actors initially responded to the notices and requested hearings, the administrative process has now moved into the formal adjudication stage, signaling a more aggressive regulatory stance against surrogate advertising practices.
Devgn’s Legal Strategy
In his petition before the Bombay High Court, Ajay Devgn has contested the fairness of the FDA’s approach. A primary pillar of his legal argument is that the notice is 'arbitrary,' as it targets the brand ambassador rather than the manufacturing entity responsible for the product's marketing strategy and classification. By challenging the liability assigned to actors for the products they endorse, Devgn is seeking to establish a precedent that separates the creative participant from the corporate entity that dictates the advertising content and product compliance.
Historical Context and Industry Implications
This case arrives at a time when the Indian government and various state health departments are intensifying their crackdown on surrogate advertising for tobacco and alcohol. Historically, brands have utilized 'brand extensions' like mouth fresheners or CDs to maintain top-of-mind awareness for prohibited items. The current legal challenge serves as a litmus test for the accountability of high-profile influencers. If the court rules in favor of the FDA, it may force a significant paradigm shift in how talent management agencies and brands structure their endorsement contracts to mitigate legal risks.
Awaiting Judicial Intervention
A division bench of the Bombay High Court, presided over by Chief Justice Mahesh Chandra Tripathi and Justice Advait Sethna, is scheduled to hear Devgn’s petition on November 4. The outcome of this hearing is highly anticipated, as it will likely determine whether the FDA can continue to hold individual actors personally liable for the perceived marketing violations of the companies they represent. As the industry watches, the intersection of public health policy and commercial freedom remains a volatile and evolving landscape.